Acasti Announces Achievement of 50% Enrollment in Pivotal Phase 3 STRIVE-ON Safety Trial
June 27, 2024 16:05 ET
|
Acasti Pharma, Inc.
PRINCETON, N.J., June 27, 2024 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (Nasdaq: ACST) (Acasti or the Company), a late-stage, biopharma company advancing GTX-104, its novel injectable formulation of...
Acasti Announces Year-End 2024 Financial Results, Provides Business Update
June 21, 2024 08:00 ET
|
Acasti Pharma, Inc.
Patient Enrollment in Pivotal STRIVE-ON Phase 3 Safety Trial for GTX-104 On-Track for Potential NDA Submission in 1H Calendar 2025Projected Cash Runway into Second Calendar Quarter 2026 ...
Acasti Pharma to Attend BIO International Convention 2024
May 28, 2024 16:05 ET
|
Acasti Pharma, Inc.
PRINCETON, N.J., May 28, 2024 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (Nasdaq: ACST) (Acasti or the Company), a late-stage, biopharma company advancing GTX-104, its novel, injectable formulation of...
Acasti Announces Third Fiscal Quarter 2024 Financial Results and Business Highlights
February 12, 2024 08:00 ET
|
Acasti Pharma, Inc.
Projected Cash Runway Extends into Second Calendar Quarter 2026, Well Beyond Potential 1H 2025 Submission of GTX-104 New Drug Application (NDA)Patient Enrollment in Pivotal STRIVE-ON Phase 3 Trial...
Acasti Announces Poster Detailing its GTX-104 STRIVE-ON Trial
February 01, 2024 08:00 ET
|
Acasti Pharma, Inc.
PRINCETON, N.J., Feb. 01, 2024 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (Nasdaq: ACST) (Acasti or the Company), a late-stage, biopharma company advancing GTX-104, its novel formulation of nimodipine...
Acasti to Participate in Upcoming San Francisco Investor Conferences in January 2024
December 13, 2023 08:00 ET
|
Acasti Pharma, Inc.
PRINCETON, N.J., Dec. 13, 2023 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (Nasdaq: ACST) (Acasti or the Company), a late-stage, biopharma company advancing GTX-104, its novel intravenous formulation of...
Acasti Announces Second Quarter 2024 Financial Results and Business Highlights
November 13, 2023 08:00 ET
|
Acasti Pharma, Inc.
Announced Dosing of First Patient in Pivotal STRIVE-ON Phase 3 Randomized Trial for GTX-104 Completed $7.5 Million Private Placement Equity Financing led by ADAR1 Partners, LP, Providing Funding Well...
Acasti Announces Dosing of First Patient in GTX-104 STRIVE-ON Trial
October 23, 2023 08:00 ET
|
Acasti Pharma, Inc.
With achievement of enrollment milestone, pivotal STRIVE-ON safety trial on track for potential NDA submission anticipated to occur in the first half of calendar 2025 Recently announced $7.5 million...
Acasti Pharma to Host KOL Event on GTX-104: A Potential New Treatment Standard for Rare and Life-Threatening aneurysmal Subarachnoid Hemorrhage (aSAH)
October 04, 2023 08:00 ET
|
Acasti Pharma, Inc.
PRINCETON, N.J., Oct. 04, 2023 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (Nasdaq: ACST) (Acasti or the Company), a late-stage, biopharma company advancing GTX-104, its novel formulation of nimodipine...
Acasti Announces $7.5 Million Private Placement Equity Financing
September 26, 2023 08:00 ET
|
Acasti Pharma, Inc.
PRINCETON, N.J., Sept. 26, 2023 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (Nasdaq: ACST) (Acasti or the Company), a late-stage, biopharma company advancing GTX-104, its novel formulation of nimodipine...